Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 5/20 | 0.51 |
| ▸ | PDPK1 | O15530 | 5/20 | 0.51 |
| ▸ | AURKB | Q96GD4 | 5/20 | 0.51 |
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.51 |
| ▸ | BTK | Q06187 | 2/20 | 0.42 |
| ▸ | JAK3 | P52333 | 1/20 | 0.42 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.39 |
| ▸ | SUV39H2 | Q9H5I1 | 6/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.37 |
| ▸ | CKS1B | P61024 | 1/20 | 0.37 |
| ▸ | SKP1 | P63208 | 1/20 | 0.37 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12119818 | 0.87 | AURKA (0.63) | AURKAPDPK1AURKBEIF2AK4BTK | |
| SCHEMBL16966450 | 0.86 | CCNC (0.38) | AURKAPDPK1AURKBEIF2AK4 | |
| SCHEMBL12119802 | 0.84 | BTK (0.59) | AURKAPDPK1AURKBBTKJAK3 | |
| SCHEMBL13354730 | 0.82 | PDPK1 (0.56) | AURKAPDPK1AURKBEIF2AK4BTK | |
| SCHEMBL12119857 | 0.81 | AURKA (0.62) | AURKAPDPK1AURKBEIF2AK4PDE10A | |
| SCHEMBL38665093 | 0.80 | EIF2AK4 (0.56) | AURKAPDPK1AURKBEIF2AK4BTK | |
| SCHEMBL38665468 | 0.80 | EIF2AK4 (0.56) | AURKAPDPK1AURKBEIF2AK4BTK | |
| SCHEMBL38665458 | 0.80 | EIF2AK4 (0.56) | AURKAPDPK1AURKBEIF2AK4BTK | |
| SCHEMBL38663357 | 0.80 | EIF2AK4 (0.56) | AURKAPDPK1AURKBEIF2AK4BTK | |
| SCHEMBL12119836 | 0.80 | AURKA (0.51) | AURKAPDPK1AURKBEIF2AK4BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2362775-B1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2015-08-05 | — | — | EP | disclosed |
| US-20110275611-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2011-11-10 | — | — | US | disclosed |
| US-20110275611-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2011-11-10 | — | — | US | disclosed |
| WO-2010059658-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2010-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275611-A1 | CHEMICAL COMPOUNDS | PDK1, PDK2, PDK3 | AURKA 298/4885PDPK1 12/4885AURKB 262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.